Drugs & Pharmaceuticals

The FDA just published an article examining the relationship between their early clinical response endpoint for community-acquired bacterial pneumonia a

By William Petri, University of Virginia

Reprinted with permission. Dr. Singer's original article can be found here. ###

By Leigh Turner, University of Minnesota

Last week, a special issue of the American Chemical Society Infectious Diseases journal focusing on antibiotics was published.  This issue is a great collection of science, researc

The FDA just revoked the emergency authorization of chloroquine and hydroxychloroquine (HCQ) - two malaria drugs that were supposed to help control coronavirus infection. But they were strong on hype and weak on results.

There are a plethora of drugs and vaccines in the pipeline to treat or prevent COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. How many of them are likely to be successful?

Reprinted by permission. Dr. Popovian's original opinion piece can be found here. ###

Over the past few months I've been arguing that remdesivir, the only approved drug for SARS-2 infection, was never going to make a meaningful impact on COVID because it is an IV-only drug, meaning that it will only be administered to ver

I want to return to my favorite topic, antibiotics, viewed through the lens of the COVID-19 pandemic. Of course, as is probably true for all of us, my perspective is colored by my own history and experience.